Funding News | NIH: National Institute of Allergy and Infectious Diseases

Funding News | NIH: National Institute of Allergy and Infectious Diseases

December 6, 2018 NIAID Funding News

Read this full issue online at http://www.niaid.nih.gov/grants-contracts/funding-news-notices

Feature Articles 

Access to Genomic Summary Results: Get up to Date on Updated Policy

The updated data management procedures under the Genomic Data Sharing policy allow unrestricted access to most NIH-supported studies for health and research purposes while considering potential risk to research participants.

Opportunities and Resources

Opportunity To Study Single-Cell Multi-Omics of HIV Persistence

NIAID is encouraging collaborations among bioinformaticians, bioengineers, HIV basic scientists, and HIV clinicians with access to relevant clinical specimens to generate novel single-cell multi-omic approaches to improve our knowledge of HIV persistence.

Check Out Funding Opportunities To Increase Men’s Engagement in HIV Prevention and Care

Apply for funding to support projects that develop and test strategies to engage and retain men along the HIV prevention and care continuum.

Team Up for Cancer Immunotherapy Research

We seek multidisciplinary, collaborative teams researching innate and adaptive immune mechanisms that contribute to tumor progression.

In The News

Provide Feedback on NIAID’s Plan To Fund More New Innovators

To create an alternative pathway for early-stage investigators to earn their first substantial award, NIAID is developing a new initiative using the NIH Director's New Innovator Award (DP2) activity code.

A New NIH Acronym To Know: BESH

NIH recently introduced a new funding opportunity announcement designation for prospective basic science studies involving human participants, to be called Basic Experimental Studies with Humans.

New Funding Opportunities

• RFA-AI-18-054, U.S.-Brazil Collaborative Biomedical Research Program (R01 Clinical Trial Optional)
• NIAID-DAIDS-NIHAI201800011, Simian Vaccine Evaluation Units (SVEUs)
• RFA-AI-18-058, Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional)
• PA-19-096, Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed)
• PAS-19-097, Research To Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-Infection (R01 Clinical Trial Not Allowed)
• PA-19-077, Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)
• PA-19-080, Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)
• PA-19-081, Advancing Development of Rapid Fungal Diagnostics (R21 Clinical Trial Not Allowed)
• PA-19-082, Novel Approaches To Understand, Prevent, Treat, and Diagnose Coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R01 Clinical Trial Not Allowed)
• PA-19-083, Novel Approaches To Understand, Prevent, Treat, and Diagnose Coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R21 Clinical Trial Not Allowed)
• PAR-19-078, Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)
• PAR-19-079, Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)
• RFA-AI-18-057, Long-Acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)

See other announcements at Opportunities & Announcements.

Send suggestions or comments to deaweb@niaid.nih.gov.

Advice Corner

Budgeting for Your Proposed Clinical Trial

If you significantly over- or underestimate your project's budget request, reviewers will take that to mean you don't grasp the scope of the work.

Reader Questions

• “How is expedited Council review different from full Council meetings?”
• “If I am promoted to associate professor, will I lose my new investigator status?”